openPR Logo
Press release

Navigawaldenstrom Macroglobulinemia By Key Players Overview (Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), etc.)

01-22-2019 08:52 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fact.MR

/ PR Agency: Fact.MR
Navigawaldenstrom Macroglobulinemia By Key Players Overview

Waldenstrom macroglobulinemia Market: Overview

Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science has made much progress and a number of new treatments for this type of cancer have been introduced. However, very few studies have been done to compare the treatment options and thus, discover the best available option. Hence, there is no single treatment available that works for all patients. Symptomatic Waldenstrom macroglobulinemia patients are kept under observation and do not receive any treatment until symptoms show up. Patients showing symptoms, such as anemia, hyperviscosity, cold-agglutinin disease, amyloidosis, peripheral neuropathy, etc., are considered for the treatment. Patients that show symptomatic hyperviscosity receive plasmapheresis along with rituximab treatment. In most cases of Waldenstrom macroglobulinemia, combination therapy with chemo and immunotherapy is recommended. Patients with this type of cancer may require stem cell transplantation during the latter stage. Hence, standard chemotherapy agents, such as chlorambucil, bendamustine, cladribine or fludarabine, etc., are not prescribed as first line therapy as they may affect the stem cells. 

Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2580

Waldenstrom macroglobulinemia Market: Drivers and Restraints

Improving treatment options and diagnosis rate are the major factors expected to drive the growth of the Waldenstrom macroglobulinemia treatment market over the forecast period. Researchers have found that targeted therapy agents, such as Velcade and Kyprolis, show improved treatment outcomes. Increased treatment seeking rate is another important factor driving the growth of the global Waldenstrom macroglobulinemia treatment market. However, lack of a single standard treatment for all patients and disease complexity are the major factors limiting the growth of global Waldenstrom macroglobulinemia treatment market. High cost of therapy and side effects are some other factors that can hamper the treatment seeking rates and in turn, affect the global market growth. 

Waldenstrom macroglobulinemia Market: Overview

The global market for Waldenstrom macroglobulinemia is expected to witness moderate growth over the forecast period. The targeted therapy segment is expected to witness considerable growth during the forecast period due to increased adoption rate of Waldenstrom macroglobulinemia targeted therapy drugs. Hospitals are the preferred distribution channel for due to requirement of skilled professionals for planning of Waldenstrom macroglobulinemia treatment. Besides, other therapies, such as stem cell transplantation, require highly advanced medical infrastructure. Majority of these treatments are covered under medical part B and hence, hospitals are a preferred distribution channel for Waldenstrom macroglobulinemia treatments.

Waldenstrom macroglobulinemia Market: Regional Outlook

Geographically, the global Waldenstrom macroglobulinemia market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant market in the global Waldenstrom macroglobulinemia market owing to high prevalence of the disease and better availability of medical resources in the region. The Waldenstrom macroglobulinemia market in Asia Pacific excluding Japan is expected to grow at a slow rate. Europe is expected to hold second largest share in the global Waldenstrom macroglobulinemia market throughout the forecast period. 

Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=2580

Waldenstrom macroglobulinemia Market: Key Players

Some of the players identified in the global include Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), Takeda Pharmaceutical Company Limited., Amgen Inc., Novartis AG and (Genentech) F. Hoffman-La Roche AG, among others. 

For more information on this report, please visit:https://www.factmr.com/report/2580/navigawaldenstrom-macroglobulinemia-market

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Navigawaldenstrom Macroglobulinemia By Key Players Overview (Baxter International Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Janssen Pharmaceutica NV (Johnson & Johnson), Merck & Co Inc., Hospira (Pfizer Inc.), etc.) here

News-ID: 1519977 • Views: 976

More Releases from Fact.MR

07-02-2020 | Health & Medicine
Fact.MR
Medical Device Contract Manufacturing Market Set for Strong Growth, Production F …
The medical device contract manufacturing market is poised to expand at a CAGR of 11.3% during the forecast period (2020-2026). This is attributed to rapidly evolving healthcare industry and increasing adoption of technologically advanced surgical procedures. A number of original equipment manufacturers (OEMs) and contract manufacturers have been focusing on advanced technologies such as robotics, 3D-printing, and minimally invasive surgeries. Mergers & acquisition activities among leading players have greatly accelerated
06-02-2020 | Health & Medicine
Fact.MR
Fluid Management Market Expected to Grow Amid Covid-19, Finds Fact.MR
Growing prevalence of chronic disease and an expansion in numbers of geriatric population is leading to an upward facing growth curve for global fluid management market over the period of 2020 to 2025, states Fact.MR. It projects a compound annual growth rate or CAGR of about 5.3% for the market over this period, helping the market push its worth up significantly. It is significant to note here that while number of
Hand Sanitizer Market to Surpass US$ 2.8 Bn, Instant Hand Sanitizer Poised to Ho …
The global hand sanitizer market is set to surpass a value of ~US$ 1.4 Bn in 2020 and is anticipated to cross US$ ~2.8 Bn during the forecast period 2020-2030. The demand for gel-based sanitizer is on the rise as compared to foaming or spray sanitizer. Thus, manufacturers are focusing on developing gel-based sanitizers as they are widely used in multiple end-use industries. With the increased penetration of the online
03-20-2020 | Health & Medicine
Fact.MR
Medical Marker Bands Market Grows on the back of Their Radiopacity and Cost-effe …
Radiopacity of medical marker bands is giving significant impetus to their demand in the medical marker bands market. The properties of medical marker bands that increases their visibility under fluoroscopes or x-ray during critical procedures is giving an uptick to their sales worldwide. Manufacturers of medical marker bands are also showing a marked preference for cost-effective materials such as polymer and tantalum instead of traditional gold, platinum and palladium. On

All 5 Releases


More Releases for Waldenstrom

Research Offers 08-Year Forecast on Waldenstrom Macroglobulinemia Market(Chemoth …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
04-22-2019 | Health & Medicine
Fact.MR
Waldenstrom Macroglobulinemia Market key Insights Based on Product Type, End-use …
Researchers have found that targeted therapy agents such as Velcade and Kyprolis are showing improved outcomes. Increased treatment-seeking rate is the other important factor projected to drive the growth of the global Waldenstrom Macroglobulinemia Market. However, lack of single standard treatment for all patients and disease complexity are the major factors expected to limit the growth of the global Waldenstrom macroglobulinemia market. High cost of therapy and side effects are
Waldenstrom Macroglobulinemia Market Challenges Analysis by 2026
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
Waldenstrom Macroglobulinemia Market | Key Players - Baxter International Inc., …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few
NavigaWaldenstrom Macroglobulinemia Market Projected to Discern Stable Expansion …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum, which leads to increased serum viscosity, and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to excess amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to symptoms. In the last few years, medical science has made much
Waldenstrom Macroglobulinemia Market Trends, Regulations And Competitive Landsca …
Waldenstrom macroglobulinemia is a rare cancer and is characterized by high level of immunoglobulin M (IgM) in the serum that causes increased serum viscosity and presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenstrom macroglobulinemia starts in B cells or B lymphocytes and leads to form large amount of IgM. Treatment options for Waldenstrom macroglobulinemia vary according to the symptoms, although standard treatments are available. In the last few